Results 1 to 10 of about 7,431 (174)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials [PDF]

open access: yesVaccines, 2023
Prevention of mpox has become an important public health interest. We aimed to evaluate the safety and immunogenicity of the Modified Vaccinia Ankara (MVA) vaccine. We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs)
Lior Nave   +6 more
doaj   +2 more sources

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara [PDF]

open access: goldBioTechniques, 2000
Recombinant vaccinia viruses are extremely valuable tools for research in molecular biology and immunology. The extension of vaccinia vector technology to replication-deficient and safety-tested virus strains such as modified vaccinia virus Ankara (MVA ...
C. Staib   +5 more
doaj   +2 more sources

Quantitative proteomics defines mechanisms of antiviral defence and cell death during modified vaccinia Ankara infection [PDF]

open access: yesNature Communications, 2023
Modified vaccinia Ankara (MVA) virus does not replicate in human cells and is the vaccine deployed to curb the current outbreak of mpox. Here, we conduct a multiplexed proteomic analysis to quantify >9000 cellular and ~80% of viral proteins throughout ...
Jonas D. Albarnaz   +12 more
doaj   +2 more sources

Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention. [PDF]

open access: hybridInt Immunopharmacol, 2023
Kandeel M   +7 more
europepmc   +2 more sources

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types [PDF]

open access: yesViruses, 2021
African swine fever (ASF) has become a global threat to the pig industry and wild suids. Within Europe, including Germany, affected wild boar populations play a major role.
Franziska Tanneberger   +4 more
doaj   +2 more sources

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. [PDF]

open access: greenJ Infect Dis, 2023
Ilchmann H   +11 more
europepmc   +3 more sources

Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory. [PDF]

open access: goldJ Immunother Cancer, 2021
Hinterberger M   +12 more
europepmc   +3 more sources

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

open access: goldPLoS ONE, 2016
BackgroundModified Vaccinia Ankara MVA-BN® is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine.
Richard N Greenberg   +15 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy